🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

20 results for “AXIM BIOTECHNOLOGIES, INC.” Clear

  1. Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion

    AXIM BIOTECHNOLOGIES, INC.

    B-cell Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial

  2. IVEMEND 150 mg powder for solution for infusion, Aprepitant Placebo Tablet, Aprepitant Teva 80 mg, harde capsules, NaCl I.V.

    AXIM BIOTECHNOLOGIES, INC.

    Delayed chemotherapy induced nausea and vomiting (CINV)

    phase 3 small molecule active

    1 trial

  3. Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution

    AXIM BIOTECHNOLOGIES, INC.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  4. ANAKINRA

    AXIM BIOTECHNOLOGIES, INC.

    Hyperinflammation, Sepsis

    phase 2 small molecule active

    1 trial

  5. Anti-GD2-800CW

    AXIM BIOTECHNOLOGIES, INC.

    Neuroblastoma

    phase 2 small molecule active

    1 trial

  6. BRIGATINIB, Alunbrig 180 mg film-coated tablets, Alunbrig 90 mg film-coated tablets, Alunbrig 30 mg film-coated tablets

    AXIM BIOTECHNOLOGIES, INC.

    Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

    phase 2 small molecule active

    1 trial

  7. Etoposide 20 mg/ml Concentrate for Solution for Infusion, Sodium Chloride 0.9% Intravenous Infusion BP, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Human Albumin Baxalta 50 g/l Solution for Infusion, Cyclophosphamide 1000 mg Powder for Solution for Injection or Infusion, Qarziba 4.5 mg/mL concentrate for solution for infusion, Dacarbazine Lipomed 200 mg powder for solu

    AXIM BIOTECHNOLOGIES, INC.

    Neuroblastoma

    phase 2 small molecule active

    1 trial

  8. IOBENGUANE (123I) , 68Ga-SSO120

    AXIM BIOTECHNOLOGIES, INC.

    neuroblastoma

    phase 2 small molecule active

    1 trial

  9. IOBENGUANE (123I) , [18F]meta-fluorobenzylguanidine

    AXIM BIOTECHNOLOGIES, INC.

    (suspision on) Neuroblastoma

    phase 2 small molecule active

    1 trial

  10. Jakavi 5 mg tablets, Venetoclax, Jakavi 20 mg tablets, Venetoclax, Jakavi 10 mg tablets, Venetoclax, Venetoclax, Venetoclax, Venetoclax, Jakavi 15 mg tablets

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  11. MB-huCART19.1

    AXIM BIOTECHNOLOGIES, INC.

    B-cell precursor ALL, B-cell Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  12. ONC201, Paxalisib

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs)

    phase 2 small molecule active

    1 trial

  13. Quizartinib

    AXIM BIOTECHNOLOGIES, INC.

    newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML

    phase 2 small molecule active

    1 trial

  14. SPRYCEL 70 mg film-coated tablets, Venetoclax, SPRYCEL 100 mg film-coated tablets, Venetoclax, SPRYCEL 20 mg film-coated tablets, Venetoclax, SPRYCEL 50 mg film-coated tablets, Venetoclax, Venetoclax, Venetoclax, SPRYCEL 10 mg/mL powder for oral suspension

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  15. Tovorafenib, Tovorafenib

    AXIM BIOTECHNOLOGIES, INC.

    craniopharyngioma

    phase 2 small molecule active

    1 trial

  16. Chewing Gum

    AXIM BIOTECHNOLOGIES, INC.

    THC

    phase 1 small molecule active

    1 trial

  17. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  18. Vyxeos Liposomal 44 mg/100 mg powder for concentrate for solution for infusion., Evoltra 1 mg/ml concentrate for solution for infusion

    AXIM BIOTECHNOLOGIES, INC.

    AML

    phase 1 small molecule active

    1 trial

  19. WT1-loaded CBDC Vaccine

    AXIM BIOTECHNOLOGIES, INC.

    AML: Acute Myeloid Leukemia/ cancer of blood and bone marrow

    phase 1 small molecule active

    1 trial

  20. Ziftomenib, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Solu-Cortef Powder for Solution for Injection or Infusion 100 mg

    AXIM BIOTECHNOLOGIES, INC.

    Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources